Orthofix International N.V. — 2017 Form 10-K
Period: Fiscal year ended December 31, 2017; fourth-quarter figures are unaudited. The company is a global musculoskeletal medical-device business with four segments: BioStim, Extremity Fixation, Spine Fixation and Biologics. The filing identifies the registrant as Orthofix International N.V.
Financial performance
| Metric | 2017 | 2016 | Change |
|---|---|---|---|
| Net sales | $433.8 million | $409.8 million | +5.9% reported; +5.5% constant currency |
| Gross profit / margin | $340.8 million / 78.6% | $321.9 million / 78.6% | Gross profit +5.9%; margin flat |
| Operating income / margin | $40.8 million / 9.4% | $21.1 million / 5.1% | Improved |
| Net income | $6.2 million; $0.34 diluted EPS | $3.1 million; $0.17 diluted EPS | Improved |
| Operating cash flow | $53.3 million | $44.7 million | +$8.6 million |
| Free cash flow | $36.4 million | $26.4 million | +$10.0 million |
Sales and marketing expense rose 9.4% to $198.4 million; general and administrative expense was essentially flat at $74.4 million; R&D increased 3.1% to $29.7 million. The company’s non-GAAP net margin—gross profit less sales and marketing expense—was $142.4 million, up 1.3%, but declined as a share of sales to 32.8% from 34.3%.
Segment sales: BioStim $185.9 million (+5.3%); Extremity Fixation $103.2 million (+0.5% reported); Spine Fixation $82.0 million (+12.8%); Biologics $62.7 million (+8.3%). Spine Fixation had the strongest growth, mainly from U.S. sales and recent products. Extremity Fixation growth was held back by restructuring and distribution changes.
Fourth quarter: Sales were $116.9 million versus $108.5 million in Q4 2016. Operating income was $17.9 million versus $7.4 million; net income was $1.6 million versus a $3.2 million net loss.
Liquidity, debt and financial position
Cash and cash equivalents were $81.2 million at year-end, up from $39.6 million. Current assets were $251.8 million and current liabilities $79.4 million. Total assets were $405.4 million, total liabilities $108.7 million, and shareholders’ equity $296.6 million. No borrowings were outstanding under the $125 million secured revolving credit facility; the facility is secured by substantially all of specified borrower and guarantor assets and includes leverage and interest-coverage covenants. The company reported covenant compliance at year-end.
Inventory increased to $81.3 million from $63.3 million; inventory turns declined to 1.1 from 1.4. Days sales outstanding increased to 53 from 52. The company reported $36.4 million in free cash flow after $16.9 million of capital expenditures.
Material changes, outlook and notable items
- Net sales increased across all four segments. Spine Fixation sales recovered from the prior-year decline; the company cited new U.S. distributors, product uptake and improved legacy-distributor engagement.
- The 2017 operating-income improvement included the absence of the $14.4 million U.S. government-resolution charge recorded in 2016, as well as a roughly $6 million insurance recovery related to prior SEC/FCPA costs. The company recorded a $2.5 million net benefit in the SEC/FCPA cost line in 2017.
- Income tax expense was $29.1 million, an 80.0% effective rate. The 2017 provision included an $8.3 million additional tax charge related to the Tax Act, chiefly deferred-tax remeasurement; the company described the tax accounting as provisional and subject to further analysis.
- The company recognized a $5.6 million other-than-temporary impairment on its eNeura debt security in 2017 and discontinued interest recognition. The security’s reported fair value was $16.1 million at year-end, based on Level 3 inputs; it matures in March 2019 and may convert to eNeura preferred stock upon a change in control.
- Two restructuring plans were underway: Extremity Fixation restructuring (cumulative costs of approximately $3.3 million) and a U.S. shared-services plan (estimated total cost approximately $1.7 million). Remaining accruals at year-end were $0.7 million and $1.1 million, respectively.
- Effective January 1, 2018, the new revenue-recognition standard was expected to materially change timing for certain stocking-distributor sales, with an approximately $5 million opening retained-earnings adjustment and increases in receivables and reductions in inventory. The filing provides no company sales or earnings guidance.
- Management cited reimbursement and pricing pressure, regulatory and product-approval demands, competition, reliance on distributors and third-party manufacturers, foreign-currency exposure, cybersecurity/privacy risks, and reliance on MTF as the sole supplier of key Trinity tissue products. It also disclosed a $1.7 million accrual for a pending post-sale Breg product-liability claim.
Most important facts for investors to verify
- Whether sales growth—especially the 12.8% Spine Fixation increase—continues, and whether stocking-distributor demand and collections support reported performance.
- How adoption of the new revenue standard affects 2018 reported sales, receivables, inventory and opening equity.
- Whether the provisional Tax Act accounting, high effective tax rate and $27.8 million of unrecognized tax benefits, interest and penalties change as tax reviews are completed.
- Recoverability and valuation assumptions for the eNeura note, including the reported $16.1 million fair value despite prior impairment and discontinued interest recognition.
- Progress and remaining costs of restructuring, and any developments in the Breg claim or other contingencies.
- Continued availability of MTF-supplied tissue, reimbursement access, distributor performance and compliance with the secured credit facility’s covenants.